All Comments by John Morris
Go to another page:
- 1
- 2
- Alzheimer’s, Primary Age-Related Tauopathy Take Separate Paths
- What About the Brain Shrinkage Seen with Aβ Removal?
- John Trojanowski, 75, a Giant in the Field of Neuropathology
- Aducanumab Approved to Treat Alzheimer’s Disease
- Aducanumab Still Needs to Prove Itself, Researchers Say
- Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
- Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.
- New Definition of Alzheimer’s Hinges on Biology, Not Symptoms
- Testing the right target and right drug at the right stage.
- A Tribute to Robert Katzman
- Operationalization of mild cognitive impairment: a graphical approach.
- AD Diagnosis: Time for Biomarkers to Weigh In?
- Chronic traumatic encephalopathy in a national football league player: part II.
- Early Intervention Trial Bears Little Fruit, but Sows Hope
- Cholinesterase Inhibitors Not What They're Cracked Up To Be?